Infinity Pharmaceuticals, Inc.

Industry

  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Technologies
      • Genomics-Proteomics
      • Molecular Diversity
      • Bioinformatics
See more in Biomedtracker

Latest on Infinity Pharmaceuticals, Inc.

Scrip

Finance Watch: A Year After Investors Denied Infinity Merger, MEI Considers Strategic Alternatives

 
• By Mandy Jackson

MEI Pharma, Inc. said on 22 July that its board of directors unanimously agreed to hire a financial consultant that can help the company assess strategic alternatives to maximize the value of its ass

Scrip

Finance Watch: Biopharma Firms Get Ahead Of Q3 Updates With Restructuring Reveals

 
• By Mandy Jackson

Cost-cutting has become the norm for biopharmaceutical companies in 2023 as drug developers struggle to raise capital for ongoing research and development programs, never mind bringing in new funding

Scrip

Finance Watch: UroGen Accesses Cash After Phase III Bladder Cancer Success

 
• By Mandy Jackson

UroGen Pharma, Ltd. anticipated filing for US Food and Drug Administration approval in 2024 for UGN-102 in the treatment of low-grade, intermediate-risk, non-muscle invasive bladder cancer (LG-IR-NMI

Scrip

Infinity And MEI Re-evaluate Business Plans After Merger Falls Through

 
• By Jessica Merrill

Infinity Pharmaceuticals, Inc. and MEI Pharma, Inc. will be considering their next steps independently after a planned merger between the cancer drug developers fell apart. The companies announced